Sharekhan

Alivus Life Sciences Ltd

Wed 21/05/2025,15:51:23 NSE: ALIVUS

₹ 1101.30 -9.90 (-0.89%)
BUY NOW Buy Alivus Life Sciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Alivus Life Sciences Ltd

Wed 21/05/2025,16:1:0

Alivus Life Sciences Ltd

Wed 21/05/2025,15:51:23 | NSE : ALIVUS

₹ 1101.30-9.90 (-0.89%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1111.20

Previous Close

₹ 1111.20

Volume

52328

Mkt Cap ( Rs. Cr)

₹13505.15

High

₹ 1124.60

Low

₹ 1094.20

52 Week High

₹ 1335.10

52 Week Low

₹ 755.95

Book Value Per Share

₹ 207.01

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alivus Life Sciences Ltd

Your Vote -

Buy

90.78%

Hold

7.28%

Sell

1.94%

90.78%

206 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

1101.30

3

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

3

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Alivus Life Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 May 2025, 7:17PM Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    16 May 2025, 1:03PM Alivus Life Sciences Limited has informed the Exchange about Link of Recording

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    16 May 2025, 1:00PM Audio recording of Q4 & FY2024-25 Earnings Call

  • Alivus Life Sciences - Outcome of Board Meeting-XBRL

    15 May 2025, 9:48PM Alivus Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on 15-May-2025 for Dividend

  • Alivus Life Sciences - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    15 May 2025, 9:15PM ALIVUS LIFE SCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfe

  • Alivus Life Sciences - Investor Presentation

    15 May 2025, 9:02PM Alivus Life Sciences Limited has informed the Exchange about Investor Presentation

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    15 May 2025, 9:02PM Please find enclose herewith Press Release of the Company for the Fourth Quarter and Year Ended March 31, 2025

  • Alivus Life Sciences - Press Release

    15 May 2025, 8:58PM Alivus Life Sciences Limited has informed the Exchange regarding a press release dated May 15, 2025, titled ""Press Release"".

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    15 May 2025, 8:55PM We are enclosing herewith the Press Release of the Company for the Fourth Quarter and Year Ended March 31, 2025

  • Alivus Life Sciences - Appointment Of Secretarial Auditor

    15 May 2025, 8:51PM Please find attached hewith intimation with respect to Appointment of Secretarial Auditor

  • Alivus Life Sciences - Outcome of Board Meeting

    15 May 2025, 8:50PM Alivus Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.

  • Alivus Life Sciences - Change in Director(s)

    15 May 2025, 8:46PM Alivus Life Sciences Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Change in Directorate

    15 May 2025, 8:45PM Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015 - Change in Directore of Alivus Life Sciences Limited.

  • Alivus Life Sciences - Corporate Action-Board to consider Dividend

    15 May 2025, 8:38PM This is to inform you that the Board of Directors of the Company has at its meeting held today, recommended payment of Final Dividend for the Financia

  • Alivus Life Sciences - Dividend

    15 May 2025, 8:36PM Alivus Life Sciences Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs.

  • Alivus Life Sciences - Board Meeting Outcome for Audited Financial Results For The Fourth Quarter And Year Ended March 31, 20

    15 May 2025, 8:32PM Audited Financial Results for the Fourth Quarter and Year ended March 31, 2025

  • Alivus Life Sciences Q4 net profit jumps 44.85% at Rs 141.87 cr

    15 May 2025, 8:30PM The company reported standalone net profit of Rs 141.87 crore for the quarter ended March 31, 2025 as compared to Rs 97.94 crore in the same period la

  • Alivus Life Sciences - Outcome of Board Meeting

    15 May 2025, 8:30PM Audited Financial Results for the Fourth Quarter and Year ended March 31, 2025

  • Alivus Life Sciences - Audited Financial Results For The Fourth Quarter And Year Ended March 31, 2025

    15 May 2025, 8:28PM Please find enclosed herewith Audited Financial Results for the Fourth Quarter and Year Ended March 31, 2025

  • Alivus Life Sciences - Trading Window-XBRL

    8 May 2025, 6:23PM Alivus Life Sciences Limited has informed the Exchange about Closure of Trading Window

  • Alivus Life Sciences - Board Meeting Intimation

    8 May 2025, 6:21PM Alivus Life Sciences Limited has informed the Exchange about Board Meeting to be held on 15-May-2025 to consider and approve the Yearly Audited Financ

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    8 May 2025, 6:19PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    8 May 2025, 6:17PM Enclosed please find herewith the details of Earnings Call slated for Friday, May 16, 2025 at 8:30 a.m. - 9:30 a.m. (IST), for your information and re

  • Alivus Life Sciences - Trading Window

    8 May 2025, 6:12PM Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulati

  • Alivus Life Sciences - Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For

    8 May 2025, 6:01PM Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 ,inter alia, to consider

  • Alivus Life Sciences - Alteration Of Capital and Fund Raising-XBRL

    30 Apr 2025, 5:36PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of Securities

  • Alivus Life Sciences - ESOP/ESOS/ESPS

    30 Apr 2025, 5:30PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of 92096 Shares.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Apr 2025, 5:26PM Allotment of Equity Shares under the \Employee Stock Options Scheme 2021\

  • Alivus Life Sciences - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    17 Apr 2025, 2:46PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Alivus Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 7:00AM As of March 2025, 74.99% is owned by Indian Promoters and 25.01% by Public. <p align=justify> Institutional holds 11.76% (Insurance Companies 0.22%) a

  • Alivus Life Sciences - General Updates

    3 Apr 2025, 7:30PM Alivus Life Sciences Limited has informed the Exchange about General Updates

  • Alivus Life Sciences - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulatio

    3 Apr 2025, 7:26PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Alivus Life Sciences - Acquisition-XBRL

    2 Apr 2025, 5:21PM Alivus Life Sciences Limited has informed the Exchange regarding Acquisition

  • Alivus Life Sciences - Acquisition

    2 Apr 2025, 4:40PM Alivus Life Sciences Limited has informed the Exchange about Acquisition

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Acquisition

    2 Apr 2025, 4:31PM Intimation of Share Purchase cum Subscription Shareholders' Agreement and Power Supply Agreement between Alivus Life Sciences Limited (formerly Glenma

  • Alivus Life Sciences - Alteration Of Capital and Fund Raising-XBRL

    7 Mar 2025, 5:07PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of Securities

  • Alivus Life Sciences - ESOP/ESOS/ESPS

    7 Mar 2025, 5:04PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of 4190 equity Shares.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    7 Mar 2025, 4:59PM Allotment of Equity Shares under the 'Glenmark Life Sciences Limited - Employee Stock Option Scheme 2021'.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Mar 2025, 2:15PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Mar 2025, 2:11PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting.

  • Alivus Life Sciences - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    27 Feb 2025, 2:27PM ALIVUS LIFE SCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfe

  • Alivus Life Sciences - Demise

    27 Feb 2025, 2:15PM Alivus Life Sciences Limited has informed the Exchange regarding Demise of Mr. Vijaykumar Ratilal Shah, Independent Director of the company on Februa

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Change in Directorate

    27 Feb 2025, 2:13PM Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Sad demise of Mr. Vijaykumar Ratilal Shah (DIN: 00376570), Independent Director of th

  • Alivus Life Sciences - Action(s) initiated or orders passed

    26 Feb 2025, 2:13PM Alivus Life Sciences Limited has informed the Exchange about Action(s) initiated or orders passed

  • Alivus Life Sciences - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    26 Feb 2025, 2:15PM Please find attached herewith disclosure under Regulation 30 of SEBI (LODR) Regulations 2015.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Feb 2025, 5:17PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Feb 2025, 5:13PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Glenmark Life Science

    11 Jul 2024 , 10:12AM Glenmark Pharmaceuticals' board of directors approved the sale of a 7.84% stake or 96,09,571 equity shares, in Glenmark Life Sciences Limited, as stated in its filing to the exchanges on Wednesday. The stake sale will be done through the stock exchanges via an offer for sale. (Negative)

  • Glenmark Life signs master supply agreement with a Japanese innovator pharma co

    19 Jan 2024 , 11:07AM Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese Innovator pharmaceutical Company

  • Glenmark Lifesciences

    31 Jul 2023 , 10:32AM The Nirma Group has emerged as the frontrunner to acquire Glenmark Life Sciences (GLS), an 82.84% subsidiary of Glenmark Pharmaceuticals. Strong positive for Glenmark Lifesciences

  • Glenmark Life Sciences report strong Q1 earnings

    21 Jul 2023 , 1:38PM Glenmark Life Sciences reported an 18% y-o-y rise in revenue to Rs 578.45 Cr in Q1FY24. It was driven by a 13.3% y-o-y increase in Generic API revenue to Rs. 504.2 Cr due to strong growth in regulated markets and steady growth in emerging markets while CDMO business recorded 91.0% growth y-o-y to Rs. 46.4 Cr due to healthy recovery in demand. As gross margins improved 385 bps y-o-y to 57% the gross profits increased 27% y-o-y to Rs. 330.41 Cr. This was driven by lower input costs and improved products mix. As a result, EBITDA increased 32% y-o-y to Rs. 193.16 Cr. while EBITDA margins remained stable y-o-y at 33% in Q1FY24. However, with 193% y-o-y rise in finance costs to Rs. 0.40 Cr the PAT increased at a slower but strong pace of 25% y-o-y to Rs. 135.45 Cr in Q1FY24. However, on a q-o-q basis, revenue and PAT declined at 7% each. Sales declined q-o-q due to high base effect. The management is hopeful of growth in the coming quarters on the back of capacity expansion and product pipeline as well as improved demand environment and supply situation. Positive for the stock.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Alivus Life Sciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 2817.372 2332.322 2138.207 2054.312 752.747
Liabilities 2817.372 2332.322 2138.207 2054.312 752.747
Equity 24.507 24.505 24.505 24.505 1.96
Gross Profit 682.584 674.246 642.293 616.06 591.074
Net Profit 485.627 470.888 466.961 418.724 351.581
Cash From Operating Activities 391.524 413.515 313.404 597.585 388.113
NPM(%) 20.34 20.62 21.6 19.72 18.64
Revenue 2386.884 2283.214 2161.22 2123.214 1885.165
Expenses 1704.3 1608.968 1518.927 1507.154 1294.091
ROE(%) 19.13 18.54 18.39 16.49 13.84

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
5 250 0 1206
17 Oct 2023 22.5 1125 0 617.7
24 Mar 2023 21 1050 0 375.3
15 Sep 2022 10.5 525 0 489
22 Nov 2021 10.5 525 0 632.7

Peers

Other companies within the same industry or sector that are comparable to Alivus Life Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 633.67 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 2309.01 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 1190.15 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 2177.20 -687.11 0.00

Company Info

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.

Read More

Parent Organisation

Alivus Life Sciences Ltd.

Founded

23/06/2011

Managing Director

Dr.Yasir Rawjee

NSE Symbol

ALIVUSEQ

FAQ

The current price of Alivus Life Sciences Ltd is ₹ 1101.30.

The 52-week high for Alivus Life Sciences Ltd is ₹ 1124.60 and the 52-week low is ₹ 1094.20.

The market capitalization of Alivus Life Sciences Ltd is currently ₹ 13505.15. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alivus Life Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alivus Life Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alivus Life Sciences Ltd shares.

The CEO of Alivus Life Sciences Ltd is Dr.Yasir Rawjee, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT